#G42

G42 launches $10bn tech investment fund/G42's Peng Xiao

Abu Dhabi-based G42 launches $10bn tech investment fund

The G42 Expansion Fund’s investment priorities will span across computing and communications technologies, intelligent mobility, clean tech and renewables, digital infrastructures, fintech, healthcare and life sciences

Hub71 AIQ

Abu Dhabi’s Hub71, AIQ partner to accelerate AI-driven transformation of the energy industry

The collaboration will see both companies accelerate the development of digital technologies to unlock greater value from oil and gas operations

G42 Cloud and Kyndryl collaborate to accelerate cloud adoption

Both companies will ensure alignment of their respective capabilities, expertise and resources that will facilitate solution planning and execution

Mubadala, G42 to set up biopharma manufacturing campus in Abu Dhabi

The facility will focus on vaccine and therapeutic products to “strengthen regional supply chains”

Beyond limits at ADIPEC

Beyond Limits shows how AI can support sustainability at ADIPEC

Recent studies found that high-performance AI frameworks powered by GPUs can improve profitability by over 13 per cent in oil field planning scenarios

Hadi Anwar, G42

Here’s how the pandemic became a catalyst for G42’s hypergrowth

AI and data analytics have enabled the healthcare industry to rapidly respond to the pandemic says Hadi Anwar, group CIO of G42

UAE’s G42 sets up data JV with Israel’s Rafael

Group 42 signed an agreement with Rafael to form Presight.AI and plans to establish a research and development center in Israel

UAE covid-19 vaccine manufacturing sinopharm

UAE to begin manufacturing ‘Hayat-Vax’ Covid-19 vaccine

The ‘Life Sciences and Vaccine Manufacturing in the UAE’ is a joint project by the Abu Dhabi-based Group 42 and China’s Sinopharm CNBG

Sinopharm

UAE to start manufacturing Sinopharm Covid-19 vaccine this year – reports

The UAE reported its highest daily rise of Covid-19 case on January 6, equalling 2,067

Mubadala acquires stake in Abu Dhabi-based AI specialist G42

Mubadala will integrate two of its entities, Injazat and Khazna, into G42

UAE vaccine trial

UAE hits target of 15,000 volunteers for Covid-19 vaccine phase III trials

The target was achieved in less than a month with individuals from 107 nationalities participating in the programme

Abu Dhabi Group 42 (G42)

Abu Dhabi-based G42 joins Israel Aerospace Industries, Rafael to combat Covid-19

They will jointly leverage their combined knowledge, human and technological assets, to accelerate the delivery of solutions to combat the pandemic

Covid-19 vaccine trials

UAE begins world’s first phase III clinical trial of Covid-19 vaccine

If successful, the vaccine could enter the market by the end of 2020 or early 2021

QuantLase Imaging Lab

UAE develops rapid coronavirus laser testing technology with results available in seconds

The device which is expected to be available in the market over the next few months is developed by QuantLase Imaging Lab and will enable rapid mass-scale testing